Welcome to our dedicated page for Covalon Technologies news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on Covalon Technologies stock.
Covalon Technologies Ltd. (CVALF) is described in its news releases as an advanced medical technologies and medical device company with expertise in advanced wound care, vascular access, and surgical consumables. The Covalon news flow often combines clinical, commercial, and financial updates, giving investors and healthcare professionals insight into how its technologies are being adopted and how the business is performing.
Recent announcements include detailed financial results, where the company has reported multiple years of revenue growth, profitability, and a debt-free balance sheet, as well as the declaration and payment of its first-ever special cash dividend. These financial updates are accompanied by commentary on revenue by product category and sales channel, including U.S. Vascular Access and Surgical Consumables, U.S. Advanced Wound Care, and International channels.
Covalon’s news also highlights clinical milestones and conference activity. The company has announced a peer-reviewed study in the Journal of the Association for Vascular Access evaluating its VALGuard ae Vascular Access Line Guard in pediatric central line care, with reported reductions in CLABSI rates. It regularly reports on participation in major professional meetings such as the Association for Vascular Access Annual Scientific Meeting, the Association of Pediatric Hematology/Oncology Nurses Conference, and the ANCC National Magnet & Pathway to Excellence Conference, where it showcases VALGuard ae, CovaClear ae, IV Clear ae, and SurgiClear ae dressings.
Investors following CVALF news can expect updates on quarterly and annual financial results, dividend decisions, board and executive changes, new clinical evidence, health economic findings, and Covalon’s presence at investor conferences such as the Planet MicroCap Showcase. This combination of financial, clinical, and market-facing news provides context on how the company positions its technologies and on the evolution of its business across its key sales channels.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) announced its participation in the Planet MicroCap Showcase: VEGAS 2025, scheduled for April 23, 2025, at 4:30 pm PST. CEO Brent Ashton will present the company's position as an undervalued, cash-rich healthcare company in the microcap sector.
Key highlights include:
- Strong financial position with over $17 million CAD cash, debt-free status, and consistent profitability
- Recognition as a 2025 OTCQX Best 50 Company and TSX Venture Top 50 company
- Focus on advanced wound care, vascular access, and surgical products
- Growing sales driven by healthcare provider and patient advocacy
The presentation will be accessible via webcast, with opportunities for 1x1 investor meetings at the Paris Hotel & Casino in Las Vegas.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has announced a significant competitive advantage following the April 2, 2025 US tariff announcements. The company's Canadian-manufactured medical products qualify for complete exemption from US tariffs under the United States-Mexico-Canada Agreement (USMCA) rules of origin requirements.
As the largest advanced wound care collagen dressing manufacturer in North America, Covalon stands to benefit substantially as competitors from the UK, Germany, and China face tariffs of 10%, 20%, and 54% respectively. The company maintains manufacturing operations in both Canada and the United States for its medical products, enabling it to maintain competitive pricing and uninterrupted access to the US market.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) held its Fiscal 2024 Annual Meeting of Shareholders on March 19, 2025. The meeting saw shareholders voting in favor of all proposed items, including the election of the Board of Directors and appointment of auditors.
The meeting achieved a 40.839% participation rate, with 11,189,231 shares represented either in person or by proxy. Detailed voting results will be available on SEDAR+, and management's presentation can be accessed through Covalon's investor relations website.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has announced its annual shareholder meeting scheduled for March 19, 2025, at 2:00pm Eastern Time. The meeting will be held in a virtual-only format, featuring a presentation from newly appointed CEO Brent Ashton, followed by a Q&A session.
Shareholders can attend via live webcast at https://virtual-meetings.tsxtrust.com/en/1738 using Meeting ID 1738 and password 'covalon2025'. Registered shareholders and appointed proxyholders will have full participation rights, including voting capabilities. Non-registered shareholders must complete additional steps to vote, including self-appointment as proxyholder and registration with TSX Trust Company.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) reported strong financial results for Q1 fiscal 2025, marking its fourth consecutive quarter of year-over-year growth. The company achieved 75% revenue growth to $8.2 million, with product revenue increasing 77% to $8.1 million.
Key highlights include:
- Gross profit of $5.0 million (61.2% margin), up 75% year-over-year
- Adjusted EBITDA of $1.6 million, a $2.8 million improvement
- Earnings per share of $0.04, up $0.07 from previous year
- 39% revenue growth from top 50 customers in US Vascular Access and Surgical Consumables
The company experienced a temporary slowdown in US Collagen business due to channel inventory normalization but expects recovery in second half of fiscal 2025. Operating expenses decreased by 15% to $3.7 million, primarily due to sales and marketing team restructuring.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has been named to the TSX Venture Exchange 2025 Top 50 Company list, recognizing it among the top fifty performing companies on the TSXV over the past year. This prestigious acknowledgment highlights the company's significant market performance and growth in the advanced medical technologies sector.
CEO Brent Ashton expressed pride in this achievement, attributing it to the team's efforts in 2024 to create and capture value through differentiated product portfolios. He emphasized that the company is in the early stages of its value creation journey and maintains optimistic views about its long-term growth potential. Covalon remains focused on expanding its investor base while strengthening relationships with existing investors across the United States, Canada, and other markets.
Covalon Technologies (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has scheduled the release of its Q1 Fiscal 2025 financial results for Friday, February 21, 2025, before markets open. The company will host a conference call and webcast to discuss the results at 8:30am ET on the same day.
Participants can join via webcast or dial in using the following numbers:
- North American Toll-Free: 1-800-549-8228
- Local (Toronto): 289-819-1520
- Local (New York): 646-564-2877
- Conference ID: 06889
A Q&A session will be available during the call, and a recording will be accessible on Covalon's website under News & Events in the Investors section.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has released a statement addressing the recent tariffs announced by President Trump on Canadian imports. The company maintains manufacturing and commercial operations on both sides of the US-Canada border and has flexibility to adjust manufacturing processes and locations to potentially mitigate negative financial impacts.
The company benefits from foreign exchange rates, with most revenues in US Dollars and costs in Canadian Dollars. The current exchange rate is 1.45 CAD/USD, compared to 1.35 a year ago. Covalon had a successful 2024 fiscal year and was ranked as the top medical device company and #4 overall on the OTCQX's Best 50 Companies list, based on one-year total return and average daily dollar volume growth.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has been named one of the 2025 OTCQX Best 50 companies, ranking #4 overall and emerging as the top Medical Device company. The recognition is based on total return and growth in average daily dollar volume throughout 2024.
The company achieved a remarkable 207% total return in 2024, significantly outperforming the Best 50 median of 74%. The OTCQX Best 50 companies collectively traded over $5.8 billion in dollar volume during 2024, with representatives from the United States, Canada, the United Kingdom, Australia, and Turkey.
CEO Brent Ashton highlighted that this achievement demonstrates Covalon's growing international investor following and recognition of its long-term potential. The company reports accelerated interest from both sophisticated microcap communities and institutional healthcare investors.
Covalon Technologies reported strong financial results for Q4 and fiscal year 2024. Q4 revenue increased 29% to $8.9 million, with full-year revenue up 17% to $31.2 million. Product revenue grew significantly, rising 35% in Q4 and 30% for the full year, driven by stronger customer demand for collagen dressings and expanded product offerings in US hospitals.
The company demonstrated improved profitability with Q4 gross profit of $5.3 million (82.8% growth) and full-year gross profit of $18.9 million (31.3% growth). Q4 Adjusted EBITDA reached $1.1 million, a $2.9 million improvement over Q4 FY'23. Earnings per share for Q4 was $0.02 and $0.11 for the full year, marking significant improvements from previous periods.
Operating expenses decreased to $4.7 million in Q4 from $5.8 million, primarily due to restructuring of sales and marketing teams. The company's gross margin improved to 60% in Q4 from 42% in the prior year.
FAQ
What is the current stock price of Covalon Technologies (CVALF)?
What is the market cap of Covalon Technologies (CVALF)?
